B+
Bull case
25%
Probability
Target price
$24.00
+65.4% vs current
BHVN
BiohavenBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-27
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$14.00
-3.5% vs current
B-
Bear case
25%
Probability
Target price
$9.00
-38.0% vs current
AI sentiment snapshot
Latest data as of 2026-07-15
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.0
Score
AI commentary
Company disclosures provide primary-source milestone support, but social data, analyst-count data, options data, and a clean post-news reaction decomposition are unavailable. The peer set is loose, and deterministic signals are negative; this remains a low-conviction monitoring setup rather than a standard-conviction thesis.
RankAlpha Sentiment Codex - 2026-07-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-13eventOpakalim epilepsy topline dataHigh impact
The company expects topline results from its pivotal opakalim epilepsy program in the second half of 2026, creating a binary validation point for a late-stage priority asset [#SEC-8K-2026-05-04].
2026-10-13catalystConfirmation of pivotal degrader-trial startsHigh impact
Biohaven expected pivotal studies for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy to initiate by mid-2026; confirmation or delay remains an execution checkpoint [#SEC-8K-2026-05-04].
2027-07-15catalystTaldefgrobep obesity topline dataHigh impact
The Phase 2 taldefgrobep alfa obesity study completed enrollment, with topline data expected in the second half of 2026; results could materially change pipeline valuation [#SEC-8K-2026-05-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-15 • Updated nightlySource: Internal modelMethodology